$10M awarded to IRIC for the development of new cancer-fighting drugs and immunotherapies
Published on June 6, 2019
The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal (UdeM) has been awarded a 10-million dollar grant from the government of Quebec’s Fonds d’accélération des collaborations en santé (FACS), to develop new cancer-fighting drugs in collaboration with biopharmaceutical company Bristol-Myers Squibb and collaborators from seven academic research centres from Quebec and abroad. This major announcement was made on June 4 by Mr. Pierre Fitzgibbon, Minister of Economy and Innovation, on the occasion of the opening of the Quebec Pavilion at the BIO International Convention, held in Philadelphia.
Financial support that provides hope
Entrusted with transforming, whenever possible, academic research into therapeutic solutions that will benefit patients, IRIC has joined with industry partners to pursue, over the next four years, a series of projects aimed at turning research efforts into therapeutic solutions that are accessible to patients. The program developed with Bristol-Myers Squibb is built on a portfolio of four oncology and cardiovascular disease projects based on innovative drug discovery concepts. They include developing drugs to reduce the side effects of treatments, using the immune system to vanquish cancer and the advancement of precision therapy to increase the effectiveness of the treatments offered.
By presenting cancer, immunotherapy and drug discovery research projects in collaboration with the biopharmaceutical community and seven Quebec academic research centres, IRIC fully met the objectives set by the FACS aimed at fostering collaborations between the players involved in the life sciences ecosystem. Among them, Michel Bouvier, Anne Marinier, Dr. Guy Sauvageau, Sylvain Meloche, Investigators at IRIC, Dr. Marc Bilodeau, Investigator at the CRCHUM, Dr. Frédéric Barabé, Investigator at the Centre de recherche du CHUL, Yoshua Bengio, founder of MILA, Dr. Nada Jabado, Investigator at the Research Institute of the McGill University Health Centre, Morag Park, Investigator at the Rosalind and Morris Goodman Cancer Research Centre of McGill University and Richard Leduc, Investigator at the Centre de recherche du CHUS.
Through this initiative, the government of Quebec is banking on their individual strengths to bolster research excellence and ensure the international acclaim of Quebec as an innovative province in the field of life sciences.
Through the Fonds d’accélération des collaborations en santé, the government of Quebec is making a long-term investment and reasserting its eagerness to support the cycle from academic research to drug discovery. It also underscores its desire to highlight research infrastructures and thereby guarantee the efficacy of the healthcare system and maximize the economic spinoffs for Quebec and the field of health sciences.